A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.

Renu VermaKesia Esther da SilvaNeesha RockwoodRoeland E WasmannNombuso YendeTaeksun SongEugene KimPaolo DentiRobert J WilkinsonJason R Andrews

Published in: medRxiv : the preprint server for health sciences (2023)

This manuscript describes the development and validation of Nanopore sequencing panel to detect host pharmacogenomic markers to guide personalized drug dosing for treatment or prevention of tuberculosis. This article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org.

Keyphrases

mycobacterium tuberculosis
adverse drug
single molecule
single cell
pulmonary tuberculosis
clinical decision support
electronic health record
hiv aids
social media
solid state
health information
drug induced
emergency department
healthcare
hepatitis c virus
deep learning